Title: To build or buy: taking a pragmatic approach to outsourcing versus in-house manufacturing

A significant milestone in the life of any biotechnology company is deciding how to manufacture your biotherapeutic, says Catarina Flyborg, Vice President of Cell and Gene Therapy, Cytiva. Overall cost will be a crucial consideration, but you also want to ensure speed to market and to build in enough flexibility in case your plans change. Whether you are developing a monoclonal antibody, a vaccine, a cell therapy or a gene therapy, there is an ever-growing number of contract manufacturers (CMOs or CDMOs) that offer a wide range of services and specialisations. It is tempting to outsource to these organisations, allowing you to focus on the core aspects of running your business, but in-house manufacturing can also bring some advantages. Here, we discuss some of the key factors that could help in making your decision on whether to build or buy.

Click Here For Complete Article Text


   Person Information
   Application Sequencing
Company  Product  Process  Other  Subjects  Event  Event  Date  Location  Publication  Publication  Date Text  Descriptor
  • Cleanroom

  • Design

  • Manufacturing

  • Outsourcing


  • Design Standards




  • Manufacturing Chemist


  • 9/17/2020


  • Article